

03-19-01

Docket # PF-0530-1 DIV

"Express Mail" mailing label number EL 743 379 240 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on 3-16-01

By: Nancy Ramos

Printed: Nancy Ramos

1c971 U.S. PTO  
09/811118

03/16/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)

Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No. 09/088,549, filed on June 1, 1998, entitled HUMAN GLUTATHIONE PEROXIDASE-6.

1. X Enclosed is a specification corresponding to the prior application, U.S. Application Serial No. 09/088,549 filed June 1, 1998, including the oath or declaration as originally signed. The specification does not contain any subject matter that would have been new matter in the prior application.
2. X With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the paper copy of the Sequence Listing for the instant divisional application is identical with the computer readable form filed with Serial No. 09/088,549, filed June 1, 1998, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. 09/088,549 as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
3. X Cancel in this application original claims 22-37 before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims.

4. X The inventors of the invention being claimed in this application are: Jennifer L. Hillman, Neil C. Corley, and Chandra Patterson.
5. X In accordance with 37 CFR 1.63(d), a copy of the originally signed declaration showing applicants' signatures as filed on October 30, 1998 is enclosed.
6.     Amend the specification by inserting after the title:
7. X The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity		Basic Fee
				Rate	Fee	\$710.00
Total Claims	21	-20	0	x \$18		\$ 18 00
Indep. Claims	2	-3	0	x \$80		\$ 0
<u>   </u> Multiple Dependent Claim(s), if any				+ \$270		\$ 0

**TOTAL FILING FEE \$ 728.00**

8.     An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
9. X Please charge Deposit Account No. 09-0108 in the amount of \$ 728.00 .

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 09-0108.

A **duplicate** copy of this Request is enclosed.

10. X New formal drawings are enclosed.
11. X The prior application is assigned of record to Incyte Pharmaceuticals, Inc., recorded on October 30, 1998, at reel 9569/frame 0041.
12.     A preliminary amendment is enclosed.
13. X Also enclosed: Return Postcard, Information Disclosure Statement, List of Cited References (PTO-1449), and a copy of previously submitted Revocation and Power of Attorney.
14. X The power of attorney of the prior application is to:

Lucy J. Billings  
Michael C. Cerrone

Reg. No. 36,749  
Reg. No. 39,132

Diana Hamlet-Cox  
Richard C. Ekstrom  
Barrie D. Greene  
Matthew R. Kaser  
Lynn E. Murry  
Shirley A. Recipon  
Susan K. Sather  
Michelle M. Stempien  
David G. Streeter  
Stephen Todd  
Christopher Turner  
P. Ben Wang


Reg. No. 33,302  
Reg. No. 37,027  
Reg. No. 46,740  
Reg. No. 44,817  
Reg. No. 42,918  
Reg. No. 47,016  
Reg. No. 44,316  
Reg. No. 41,327  
Reg. No. 43,168  
Reg. No. 47,139  
Reg. No. 45,167  
Reg. No. 41,420

- a. ☐ An associate power of attorney is attached.
- b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. ☒ Address all future correspondence to:

INCYTE GENOMICS, INC.  
PATENT DEPARTMENT  
3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555, Fax: (650) 845-4166

Date: 16 March 2001


By:



Richard C. Ekstrom  
Reg. No. 37,027  
Direct Dial Telephone: (650) 843-7352

Date: Mar. 16, 2001.

By:



Terence P. Lo, Ph.D.  
Limited Recognition (37 C.F.R. § 10.9(b)) attached  
Direct Dial Telephone: (650) 621-8581

- ☐ Inventor(s)  
☐ Assignee of complete interest  
☒ Attorney or agent of record  
☐ Filed under 37 CFR 1.34(a)  
☐ Registration number if acting under 37 CFR 1.34(a) \_\_\_\_\_